Syngene, a leading global CRDMO with over 30 years of experience in solving complex R&D challenges, delivers integrated drug discovery, development, and manufacturing services across small and large molecules, including niche modalities such as ADCs, peptides, and oligonucleotides. Syngene’s clientele includes world leaders across diverse sectors, ranging from global multinationals to small and medium-sized start-ups. As a strategic partner, Syngene offers innovative, flexible, and efficient approaches to scale rapidly, enabling faster go-to-market and improved access to patients. At this year’s event, Syngene showcases its small molecule and biologics capabilities, including its new facility in Bayview, Maryland, U.S., and its commitment to sustainability—recognised by TIME magazine as one of the world’s most sustainable pharmaceutical companies. Visitors will experience Syngene’s elite-level client-centricity, robust supply chain, and scientific excellence at scale.
